The $1,000-a-Month Pill That's Eating Your Paycheck
GLP-1 drugs are backed by some of the strongest clinical evidence in obesity medicine. They are also priced so aggressively that covering them threatens to collapse employer insurance pools. The problem is not the medication. The problem is pharmaceutical pricing that holds both patients and insurers hostage.
By Dr. Alex Chen · 3 min read